Ancora Advisors LLC Acquires 8,141 Shares of Pfizer Inc. (PFE)  Donald Scott | Aug 17th, 2018
Ancora Advisors LLC boosted its holdings in shares of Pfizer Inc. (NYSE:PFE) by 2.9% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 289,460 shares of the biopharmaceutical company's stock after buying an additional 8,141 shares during the quarter. Ancora Advisors LLC's holdings in Pfizer were worth $10,273,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Ballew Advisors Inc bought a new position in shares of Pfizer in the first quarter worth approximately $102,000. Earnest Partners LLC bought a new position in shares of Pfizer in the fourth quarter worth approximately $105,000. First Dallas Securities Inc. bought a new position in shares of Pfizer in the fourth quarter worth approximately $118,000. Woodard & Co. Asset Management Group Inc. ADV bought a new position in shares of Pfizer in the fourth quarter worth approximately $118,000. Finally, Delpha Capital Management LLC bought a new position in shares of Pfizer in the fourth quarter worth approximately $126,000. Institutional investors own 69.28% of the company's stock. Get Pfizer alerts:
PFE has been the subject of a number of recent analyst reports. ValuEngine lowered shares of Pfizer from a "buy" rating to a "hold" rating in a research report on Wednesday, May 2nd. JPMorgan Chase & Co. reiterated a "buy" rating and issued a $42.00 price target on shares of Pfizer in a research report on Wednesday, May 2nd. BMO Capital Markets dropped their price target on shares of Pfizer from $43.00 to $42.00 and set an "outperform" rating for the company in a research report on Wednesday, May 2nd. Morningstar set a $43.50 price target on shares of Pfizer and gave the stock a "buy" rating in a research report on Wednesday, May 2nd. Finally, DZ Bank reiterated a "sell" rating on shares of Pfizer in a research report on Thursday, May 3rd. Two investment analysts have rated the stock with a sell rating, twelve have given a hold rating and nine have assigned a buy rating to the company's stock. The company presently has an average rating of "Hold" and an average target price of $40.95.
PFE stock opened at $41.42 on Friday. Pfizer Inc. has a one year low of $32.32 and a one year high of $41.64. The company has a current ratio of 1.16, a quick ratio of 0.91 and a debt-to-equity ratio of 0.41. The firm has a market capitalization of $243.65 billion, a PE ratio of 15.63, a P/E/G ratio of 1.98 and a beta of 0.96.
Pfizer (NYSE:PFE) last released its earnings results on Tuesday, July 31st. The biopharmaceutical company reported $0.81 EPS for the quarter, topping the consensus estimate of $0.74 by $0.07. Pfizer had a net margin of 42.35% and a return on equity of 25.35%. The firm had revenue of $13.47 billion for the quarter, compared to the consensus estimate of $13.30 billion. During the same quarter in the previous year, the firm earned $0.67 earnings per share. The company's quarterly revenue was up 4.4% compared to the same quarter last year. equities research analysts predict that Pfizer Inc. will post 2.99 EPS for the current year.
The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 4th. Stockholders of record on Friday, August 3rd will be issued a $0.34 dividend. This represents a $1.36 annualized dividend and a dividend yield of 3.28%. The ex-dividend date is Thursday, August 2nd. Pfizer's dividend payout ratio (DPR) is presently 51.32%.
In related news, Director W Don Cornwell sold 5,223 shares of the company's stock in a transaction on Monday, June 4th. The shares were sold at an average price of $36.40, for a total transaction of $190,117.20. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink . Also, insider Laurie J. Olson sold 10,214 shares of the company's stock in a transaction on Monday, August 13th. The shares were sold at an average price of $41.00, for a total transaction of $418,774.00. Following the sale, the insider now directly owns 72,672 shares in the company, valued at approximately $2,979,552. The disclosure for this sale can be found here . Insiders sold 785,453 shares of company stock worth $29,937,357 in the last three months. Insiders own 0.06% of the company's stock.
Pfizer Profile
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.
Read More: Should you buy a closed-end mutual fund?
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE). Pfizer Pfize